Brief: Homology Medicines Reports Fourth Quarter And Full Year 2022 Results
09/03/2023 21:14
March 9 (Reuters) - Homology Medicines Inc FIXX.O :
* HOMOLOGY MEDICINES REPORTS FOURTH QUARTER AND FULL YEAR
2022
FINANCIAL RESULTS AND RECENT HIGHLIGHTS
* HOMOLOGY MEDICINES INC - ANTICIPATED CASH RUNWAY INTO Q4
2024
ENABLES EXECUTION AGAINST KEY MILESTONES
* HOMOLOGY MEDICINES INC - QTRLY LOSS PER SHARE $0.60
Source text for Eikon: ID:nGNX54yqG9
Further company coverage: FIXX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Q32 Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Q32 Bio Reports Second Quarter 2026 Financial Results And Provides Corporate Update
Q32 Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Q32 Bio Inc expected to post a loss of 54 cents a share - Earnings Preview